Immunome Q2 EPS $(0.46) Misses $(0.16) Estimate, Sales $4.26M
Portfolio Pulse from Benzinga Newsdesk
Immunome (NASDAQ:IMNM) reported Q2 losses of $(0.46) per share, missing the analyst consensus estimate of $(0.16) by 187.5%. This is a 37.84% increase over losses of $(0.74) per share from the same period last year. The company reported $4.26 million in sales this quarter.
August 09, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Immunome's Q2 earnings missed analyst estimates by a significant margin, which could negatively impact investor sentiment.
Immunome's Q2 earnings missed analyst estimates by a significant margin. This could lead to a decrease in investor confidence and potentially a drop in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100